Phase III Study of AK112 for NSCLC Patients
Trial details
- Registry ID
- NCT06396065
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Carboplatin; Pemetrexed
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase III Study of AK112 for NSCLC PatientsNCT06396065 | Summit Therapeutics | Phase 3 | Active not recruiting | 2025-04-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |